Glucocorticoid-induced osteoporosis - a disorder of mesenchymal stromal cells?

Frontiers in Endocrinology

Volumn 2, Issue AUG, 2010, Pages

  Hardy, Rowan ^a   Cooper, Mark S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Glucocorticoids; Osteoporosis; Stromal,Mesenchymal

Indexed keywords

EID: 84866279339     PISSN: None     EISSN: 16642392     Source Type: Journal    
DOI: 10.3389/fendo.2011.00024     Document Type: Article

References (78)

1. Aboudrar, S., Sempore, B., Koubi, H., Dechaud, H., and Desplanches, D. (1993). Effects of adrenalectomy or RU-486 on rat muscle fibers dur- ing hindlimb suspension. J. Appl. Physiol. 75, 2767-2773.
2. Abraham, S. M., Lawrence, T., Kleiman, A., Warden, P., Medghalchi, M., Tuckermann, J., Saklatvala, J., and Clark, A. R. (2006). Antiinflam- matory effects of dexamethasone are partly dependent on induc- tion of dual specificity phos- phatase 1. J. Exp. Med. 203, 1883-1889.
3. Adachi, J. D., Bensen, W. G., Brown, J., Hanley, D., Hodsman, A., Josse, R., Kendler, D. L., Lentle, B., Olszynski, W., Ste-Marie, L. G., Tenenhouse, A., and Chines, A. A. (1997). Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N.Engl.J.Med.337, 382-387.
4. Adachi, J. D., Saag, K. G., Delmas, P. D., Liberman, U. A., Emkey, R. D., See- man, E., Lane, N. E., Kaufman, J. M., Poubelle, P. E., Hawkins, F., Correa- Rotter, R., Menkes, C. J., Rodriguez- Portales, J. A., Schnitzer, T. J., Block, J. A.,Wing, J., McIlwain, H. H.,West- hovens, R., Brown, J., Melo-Gomes, J. A., Gruber, B. L., Yanover, M. J., Leite, M. O., Siminoski, K. G., Nevitt, M. C., Sharp, J. T., Malice, M. P., Dumortier, T., Czachur, M., Caro- fano, W., and Daifotis, A. (2001). Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glu- cocorticoids: a randomized, double- blind, placebo-controlled extension trial. Arthritis Rheum. 44, 202-211.
5. Allen, D. B., Mullen, M., and Mullen, B. (1994). A meta-analysis of the effect of oral and inhaled corticosteroids on growth. J. Allergy Clin. Immunol. 93, 967-976.
6. Belvisi, M. G., Wicks, S. L., Bat- tram, C. H., Bottoms, S. E., Red- ford, J. E., Woodman, P., Brown, T. J., Webber, S. E., and Foster, M. L. (2001). Therapeutic benefit of a dissociated glucocorticoid and the relevance of in vitro separa- tion of transrepression from trans- activation activity. J. Immunol. 166, 1975-1982.
7. Bujalska, I. J., Kumar, S., Hewison, M., and Stewart, P. M. (1999). Differentiation of adipose stro- mal cells: the roles of gluco- corticoids and 11β-hydroxysteroid dehydrogenase. Endocrinology 140, 3188-3196.
8. Bujalska, I. J., Kumar, S., and Stew- art, P. M. (1997). Does central obesity reflect "Cushing's disease of the omentum?" Lancet 349, 1210-1213.
9. Burt, M. G., Gibney, J., and Ho, K. K. (2006). Characterization of the metabolic phenotypes of Cushing's syndrome and growth hormone deficiency: a study of body composition and energy metabo- lism. Clin. Endocrinol. (Oxf) 64, 436-443.
10. Chapman, K. E., Coutinho, A. E., Gray, M., Gilmour, J. S., Savill, J. S., and Seckl, J. R. (2009). The role and regulation of 11beta- hydroxysteroid dehydrogenase type 1 in the inflammatory response. Mol. Cell. Endocrinol. 301, 123-131.
11. Chiodini, I., Morelli, V., Masserini, B., Salcuni, A. S., Eller-Vainicher, C., Viti, R., Coletti, F., Guglielmi, G., Battista, C., Carnevale, V., Iorio, L., Beck-Peccoz, P., Arosio, M., Ambrosi,B.,and Scillitani,A. (2009). Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal incidentalomas with and with- out subclinical hypercortisolism: an Italian Italian multicenter study. J. Clin. Endocrinol. Metab. 94, 3207-3214.
12. Chrysis, D., Ritzen, E. M., and Saven- dahl, L. (2003). Growth retardation induced by dexamethasone is asso- ciated with increased apoptosis of the growth plate chondrocytes. J. Endocrinol. 176, 331-337.
13. Cohen, S., Levy, R. M., Keller, M., Boling, E., Emkey, R. D., Green- wald, M., Zizic, T. M., Wallach, S., Sewell, K. L., Lukert, B. P., Axel- rod, D. W., and Chines, A. A. (1999). Risedronate therapy pre- vents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo- controlled, parallel-group study. Arthritis Rheum. 42, 2309-2318.
14. Cooper,M. S. (2004). Sensitivity of bone to glucocorticoids. Clin. Sci. (Lond.) 107, 111-123.
15. Cooper, M. S., Bujalska, I., Rabbitt, E., Walker, E. A., Bland, R., Shep- pard, M. C., Hewison, M., and Stewart, P. M. (2001). Modula- tion of 11β-hydroxysteroid dehy- drogenase isozymes by proinflam- matory cytokines in osteoblasts: an autocrine switch from glucocorti- coid inactivation to activation. J. Bone Miner. Res. 16, 1037-1044.
16. Cooper, M. S., Rabbitt, E. H., Goddard, P. E., Bartlett, W. A., Hewison, M., and Stewart,P. M. (2002). Osteoblas- tic 11β-hydroxysteroid dehydroge- nase type 1 activity increases with age and glucocorticoid expo- sure. J. Bone Miner. Res. 17, 979-986.
17. Cooper, M. S., and Stewart, P. M. (2003). Corticosteroid insufficiency in acutely ill patients. N.Engl.J.Med. 348, 727-734.
18. Cooper,M. S.,and Stewart,P. M. (2009). 11Beta-hydroxysteroid dehydroge- nase type 1 and its role in the hypothalamus-pituitary-adrenal axis, metabolic syndrome, and inflammation. J. Clin. Endocrinol. Metab. 94, 4645-4654.
19. Cooper, M. S., Walker, E. A., Bland, R., Fraser, W. D., Hewison, M., and Stewart, P. M. (2000). Expres- sion and functional consequences of 11β-hydroxysteroid dehydroge- nase activity in human bone. Bone 27, 375-381.
20. Cushing, H. W. (1932). The basophil adenomas of the pituitary body and their clinical manifestations (pitu- itary basophilism). Bull. Johns Hop- kins Hosp. 50, 137-195.
21. da Silva, M. L., Chagastelles, P. C., and Nardi, N. B. (2006). Mesenchy- mal stem cells reside in virtually all post-natal organs and tissues. J. Cell Sci. 119, 2204-2213.
22. Derfoul, A., Perkins, G. L., Hall, D. J., and Tuan, R. S. (2006). Glucocorti- coids promote chondrogenic differ- entiation of adult human mesenchy- mal stem cells by enhancing expres- sion of cartilage extracellular matrix genes. Stem Cells 24, 1487-1495.
23. Eijken, M., Hewison, M., Cooper, M. S., De Jong, F. H., Chiba, H., Stewart, P. M., Uitterlinden, A. G., Pols, H. A., and van Leeuwen, J. P. (2005). 11β-Hydroxysteroid dehydrogenase expression and glucocorticoid syn- thesis are directed by a molecu- lar switch during osteoblast dif- ferentiation. Mol. Endocrinol. 19, 621-631.
24. Fernandez-Rodriguez, E., Stewart, P. M., and Cooper, M. S. (2009). The pituitary-adrenal axis and body composition. Pituitary 12, 105-115.
25. Fried, S. K., Russell, C. D., Grauso, N. L., and Brolin, R. E. (1993). Lipopro- tein lipase regulation by insulin and glucocorticoid in subcutaneous and omental adipose tissues of obese women and men. J. Clin. Invest. 92, 2191-2198.
26. Gong, R., Morris, D. J., and Brem, A. S. (2008). Variable expression of 11beta Hydroxysteroid dehydroge- nase (11beta-HSD) isoforms in vas- cular endothelial cells. Steroids 73, 1187-1196.
27. Hardy, R., and Cooper, M. S. (2010). Adrenal gland and bone. Arch. Biochem. Biophys. 503, 137-145.
28. Hardy, R., Rabbitt, E. H., Filer, A., Emery, P., Hewison, M., Stewart, P. M., Gittoes, N. J., Buckley, C. D., Raza, K., and Cooper, M. S. (2008). Local and systemic glucocorticoid metabolism in inflammatory arthri- tis. Ann. Rheum. Dis. 67, 1204-1210.
29. Hardy, R. S., Filer,A., Cooper, M. S., Par- sonage, G., Raza, K., Hardie, D. L., Rabbitt, E. H., Stewart, P. M., Buck- ley, C. D., and Hewison, M. (2006). Differential expression, function and response to inflammatory stimuli of 11β-hydroxysteroid dehydroge- nase type 1 in human fibroblasts: a mechanism for tissue-specific regu- lation of inflammation. Arthritis Res. Ther. 8, R108.
30. Haynesworth, S. E., Goshima, J., Gold- berg, V. M., and Caplan, A. I. (1992). Characterization of cells with osteogenic potential from human marrow. Bone 13, 81-88.
31. Hofbauer, L. C., Gori, F., Riggs, B. L., Lacey, D. L., Dunstan, C. R., Spelsberg, T. C., and Khosla, S. (1999). Stimulation of osteopro- tegerin ligand and inhibition of osteoprotegerin production by glu- cocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid- induced osteoporosis. Endocrinology 140, 4382-4389.
32. Hu, Z., Wang, H., Lee, I. H., Du, J., and Mitch, W. E. (2009). Endoge- nous glucocorticoids and impaired insulin signaling are both required to stimulate muscle wasting under pathophysiological conditions in mice. J. Clin. Invest. 119, 3059-3069.
33. Huizenga, N. A., Koper, J. W., De Lange, P., Pols, H. A., Stolk, R. P., Burger, H., Grobbee, D. E., Brinkmann, A. O., De Jong, F. H., and Lam- berts, S. W. (1998). A polymor- phism in the glucocorticoid recep- tor gene may be associated with and increased sensitivity to glucocorti- coids in vivo. J. Clin. Endocrinol. Metab. 83, 144-151.
34. Issekutz, B. Jr., and Borkow, I. (1972). Effect of catecholamines and dibutyryl-cyclic-AMP on glu- cose turnover,plasma free fatty acids, and insulin in dogs treated with methylprednisolone. Can. J. Physiol. Pharmacol. 50, 999-1006.
35. Kato,Y., and Gospodarowicz, D. (1985). Stimulation by glucocorticoid of the synthesis of cartilage-matrix proteo- glycans produced by rabbit costal chondrocytes in vitro. J. Biol. Chem. 260, 2364-2373.
36. Kaur, K., Hardy, R., Ahasan, M. M., Eijken, M., van Leeuwen, J. P., Filer, A., Thomas, A. M., Raza, K., Buck- ley, C. D., Stewart, P. M., Rabbitt, E. H., Hewison, M., and Cooper, M. S. (2010). Synergistic induction of local glucocorticoid generation by inflammatory cytokines and gluco- corticoids: implications for inflam- mation associated bone loss. Ann. Rheum. Dis. 69, 1185-1190.
37. Lai, H. C., FitzSimmons, S. C., Allen, D. B., Kosorok, M. R., Rosenstein, B. J., Campbell, P. W., and Far- rell, P. M. (2000). Risk of persistent growth impairment after alternate- day prednisone treatment in chil- dren with cystic fibrosis. N. Engl. J. Med. 342, 851-859.
38. Lane, N. E., Yao, W., Balooch, M., Nalla, R. K., Balooch, G., Habelitz, S., Kinney, J. H., and Bonewald, L. F. (2006). Glucocorticoid-treated mice have localized changes in tra- becular bone material properties and osteocyte lacunar size that are not observed in placebo-treated or estrogen-deficient mice. J. Bone Miner. Res. 21, 466-476.
39. MacDougald, O. A., and Lane, M. D. (1995). Transcriptional regulation of gene expression during adipocyte differentiation. Annu. Rev. Biochem. 64, 345-373.
40. Mackay, A. M., Beck, S. C., Murphy, J. M., Barry, F. P., Chichester, C. O., and Pittenger, M. F. (1998). Chondrogenic differentiation of cul- tured human mesenchymal stem cells from marrow. Tissue Eng. 4, 415-428.
41. Manenschijn, L., van den Akker, E. L., Lamberts, S. W., and van Rossum, E. F. (2009). Clinical features asso- ciated with glucocorticoid receptor polymorphisms. An overview. Ann. N. Y. Acad. Sci. 1179, 179-198.
42. Medici, D., Shore, E. M., Lounev, V. Y., Kaplan, F. S., Kalluri, R., and Olsen, B. R. (2010). Conversion of vascu- lar endothelial cells into multipo- tent stem-like cells. Nat. Med. 16, 1400-1406.
43. Morgan, S. A., Sherlock, M., Gathercole, L. L., Lavery, G. G., Lenaghan, C., Bujalska, I. J., Laber, D., Yu, A., Con- vey, G., Mayers, R., Hegyi, K., Sethi, J. K., Stewart, P. M., Smith, D. M., and Tomlinson, J. W. (2009). 11beta- hydroxysteroid dehydrogenase type 1 regulates glucocorticoid-induced insulin resistance in skeletal muscle. Diabetes 58, 2506-2515.
44. O'Brien, C. A., Jia, D., Plotkin, L. I., Bellido, T., Powers, C. C., Stewart, S. A., Manolagas, S. C., and Wein- stein, R. S. (2004). Glucocorticoids act directly on osteoblasts and osteo- cytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 145, 1835-1841.
45. Oshina, H., Sotome, S., Yoshii, T., Tori- goe, I., Sugata, Y., Maehara, H., Marukawa, E., Omura, K., and Shi- nomiya, K. (2007). Effects of contin- uous dexamethasone treatment on differentiation capabilities of bone marrow-derived mesenchymal cells. Bone 41, 575-583.
46. Parsonage, G., Filer, A. D., Haworth, O., Nash, G. B., Rainger, G. E., Salmon, M., and Buckley, C. D. (2005). A stromal address code defined by fibroblasts. Trends Immunol. 26, 150-156.
47. Paulsen, S. K., Pedersen, S. B., Fisker, S., and Richelsen, B. (2007). 11Beta- HSD type 1 expression in human adipose tissue: impact of gender, obesity, and fat localization. Obesity (Silver Spring) 15, 1954-1960.
48. Pereira,R. M.,and Freire de,C. J. (2011). Glucocorticoid-induced myopathy. Joint Bone Spine 78, 41-44.
49. Phillips, P. J., and Weightman, W. (2007). Skin and Cushing syndrome. Aust. Fam. Physician 36, 545-547.
50. Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simon- etti, D. W., Craig, S., and Marshak, D. R. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284, 143-147.
51. Ponec, M., de, H. C., Bachra, B. N., and Polano, M. K. (1977). Effects of glucocorticosteroids on primary human skin fibroblasts. I. Inhibition of the proliferation of cultured pri- mary human skin and mouse L929 fibroblasts. Arch. Dermatol. Res. 259, 117-123.
52. Rabbitt, E., Lavery, G. G., Walker, E. A., Cooper, M. S., Stewart, P. M., and Hewison, M. (2002). Pre-receptor regulation of glucocorticoid action by 11β-hydroxysteroid dehydroge- nase: a novel determinant of cell proliferation. FASEB J. 16, 36-44.
53. Rauch, A., Seitz, S., Baschant, U., Schilling, A. F., Illing, A., Stride, B., Kirilov, M., Mandic, V., Takacz, A., Schmidt-Ullrich, R., Ostermay, S., Schinke, T., Spanbroek, R., Zaiss, M. M., Angel, P. E., Lerner, U. H., David, J. P., Reichardt, H. M., Amling, M., Schutz, G., and Tuckermann, J. P. (2010). Glucocorticoids sup- press bone formation by attenuat- ing osteoblast differentiation via the monomeric glucocorticoid receptor. Cell Metab. 11, 517-531.
54. Raza, K., Hardy, R., and Cooper, M. S. (2010). The 11beta-hydroxysteroid dehydrogenase enzymes - arbiters of the effects of glucocorticoids in synovium and bone. Rheumatology (Oxford) 49, 2016-2023.
55. Rebuffe-Scrive, M., Krotkiewski, M., Elfverson, J., and Bjorntorp, P. (1988). Muscle and adipose tis- sue morphology and metabolism in Cushing's syndrome. J. Clin. Endocrinol. Metab. 67, 1122-1128.
56. Reid, D. M., Devogelaer, J. P., Saag, K., Roux, C., Lau, C. S., Reginster, J. Y., Papanastasiou, P., Ferreira, A., Hartl, F., Fashola, T., Mesenbrink, P., and Sambrook, P. N. (2009). Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporo- sis (HORIZON): a multicentre, double-blind, double-dummy, ran- domised controlled trial. Lancet 373, 1253-1263.
57. Reynolds, R. M., Dennison, E. M., Walker, B. R., Syddall, H. E., Wood, P. J., Andrew, R., Phillips, D. I., and Cooper, C. (2005). Cortisol secre- tion and rate of bone loss in a population-based cohort of elderly men and women. Calcif. Tissue Int. 77, 134-138.
58. Rhen, T., and Cidlowski, J. A. (2005). Antiinflammatory action of gluco- corticoids - new mechanisms for old drugs. N.Engl.J.Med.353, 1711-1723.
59. Rosenstock, J., Banarer, S., Fonseca, V. A., Inzucchi, S. E., Sun, W., Yao, W., Hollis, G., Flores, R., Levy, R., Williams, W. V., Seckl, J. R., and Huber, R. (2010). The 11-beta- hydroxysteroid dehydrogenase type 1 inhibitor INCB13739 improves hyperglycemia in patients with type 2 diabetes inadequately controlled by metformin monotherapy. Dia- betes Care 33, 1516-1522.
60. Saag, K. G., Shane, E., Boonen, S., Marin, F., Donley, D. W., Taylor, K. A., Dalsky, G. P., and Mar- cus, R. (2007). Teriparatide or alen- dronate in glucocorticoid-induced osteoporosis. N.Engl.J.Med.357, 2028-2039.
61. Schoepe, S., Schacke, H., May, E., and Asadullah,K. (2006). Glucocorticoid therapy-induced skin atrophy. Exp. Dermatol. 15, 406-420.
62. Schrier, L., Ferns, S. P., Barnes, K. M., Emons, J. A., Newman, E. I., Nils- son, O., and Baron, J. (2006). Deple- tion of resting zone chondrocytes during growth plate senescence. J. Endocrinol. 189, 27-36.
63. Shalhoub, V., Conlon, D., Tassinari, M., Quinn, C., Partridge, N., Stein, G. S., and Lian, J. B. (1992). Gluco- corticoids promote development of the osteoblast phenotype by selec- tively modulating expression of cell growth and differentiation associ- ated genes. J. Cell. Biochem. 50, 425-440.
64. Sher, L. B., Harrison, J. R., Adams, D. J., and Kream, B. E. (2006). Impaired cortical bone acquisition and osteoblast differentiation in mice with osteoblast-targeted dis- ruption of glucocorticoid signaling. Calcif. Tissue Int. 79, 118-125.
65. Sher, L. B., Woitge, H. W., Adams, D. J., Gronowicz, G. A., Krozowski, Z., Harrison, J. R., and Kream, B. E. (2004). Transgenic expression of 11β-hydroxysteroid dehydrogenase type 2 in osteoblasts reveals an ana- bolic role for endogenous glucocor- ticoids in bone. Endocrinology 145, 922-929.
66. Stahn, C., and Buttgereit, F. (2008). Genomic and nongenomic effects of glucocorticoids. Nat. Clin. Pract. Rheumatol. 4, 525-533.
67. Stewart, P. M.,Wallace,A. M.,Valentino, R., Burt, D., Shackleton, C. H., and Edwards, C. R. (1987). Mineralo- corticoid activity of liquorice: 11β- hydroxysteroid dehydrogenase defi- ciency comes of age. Lancet 2, 821-824.
68. Tanaka, H., Ichikawa,Y.,Akama, H., and Homma, M. (1989). In vivo respon- siveness to glucocorticoid correlated with glucocorticoid receptor con- tent in peripheral blood leukocytes in normal humans. Acta Endocrinol. 121, 470-476.
69. Thieringer, R., Le Grand, C. B., Carbin, L., Cai, T. Q., Wong, B., Wright, S. D., and Hermanowski-Vosatka, A. (2001). 11 Beta-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differenti- ation to macrophages. J. Immunol. 167, 30-35.
70. Tiao, G., Fagan, J., Roegner, V., Lieber- man,M.,Wang,J. J.,Fischer,J. E.,and Hasselgren, P. O. (1996). Energy- ubiquitin-dependent muscle prote- olysis during sepsis in rats is reg- ulated by glucocorticoids. J. Clin. Invest. 97, 339-348.
71. Tomlinson, J. W., Moore, J., Cooper, M. S., Bujalska, I., Shahmanesh, M., Burt, C., Strain, A., Hewison, M., and Stewart, P. M. (2001). Regulation of expression of 11β- hydroxysteroid dehydrogenase type 1 in adipose tissue: tissue-specific induction by cytokines. Endocrinol- ogy 142, 1982-1989.
72. Van Cauter, E., Leproult, R., and Kupfer, D. J. (1996). Effects of gender and age on the levels and circadian rhyth- micity of plasma cortisol. J. Clin. Endocrinol. Metab. 81, 2468-2473.
73. van Staa, T. P., Leufkens, H. G., Aben- haim, L., Zhang, B., and Cooper, C. (2000). Use of oral corticosteroids and risk of fractures. J. Bone Miner. Res. 15, 993-1000.
74. Wang,F. S.,Ko,J.Y.,Yeh,D. W.,Ke,H. C., and Wu, H. L. (2008). Modulation of Dickkopf-1 attenuates glucocor- ticoid induction of osteoblast apop- tosis, adipocytic differentiation, and bone mass loss. Endocrinology 149, 1793-1801.
75. Wang, F. S., Lin, C. L., Chen, Y. J., Wang, C. J., Yang, K. D., Huang, Y. T., Sun, Y. C., and Huang, H. C. (2005). Secreted frizzled-related protein 1 modulates glucocorticoid attenuation of osteogenic activities and bone mass. Endocrinology 146, 2415-2423.
76. Weinstein, R. S., Jilka, R. L., Parfitt, A. M., and Manolagas, S. C. (1998). Inhibition of osteoblasto- genesis and promotion of apop- tosis of osteoblasts and osteocytes by glucocorticoids. Potential mech- anisms of their deleterious effects on bone. J. Clin. Invest. 102, 274-282.
77. Weinstein, R. S., Wan, C., Liu, Q., Wang, Y., Almeida, M., O'Brien, C. A., Thostenson, J., Roberson, P. K., Boskey, A. L., Clemens, T. L., and Manolagas, S. C. (2010). Endoge- nous glucocorticoids decrease skele- tal angiogenesis, vascularity, hydra- tion, and strength in aged mice. Aging Cell 9, 147-161.
78. Yao, W., Cheng, Z., Pham, A., Busse, C., Zimmermann, E. A., Ritchie, R. O., and Lane, N. E. (2008). Glucocorticoid-induced bone loss in mice can be reversed by the actions of parathyroid hormone and rise- dronate on different pathways for bone formation and mineralization. Arthritis Rheum. 58, 3485-3497.